Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
BLENREP is indicated in adults for the treatment of multiple myeloma:1
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
- In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]
Read the draft guidance from NICE for BLENREP in combination with bortezomib and dexamethasone.
By clicking this link, you will leave GSKPro.com, a website provided by GSK. This link will take you to a website to which our Privacy Statement, Cookie Statement and Terms of Use Agreement do not apply. GSK does not endorse and/or influence the content found on websites not owned/operated by GSK.
Abbreviations
2L, second line; NICE, National Institute for Health and Care Excellence.
References
- BLENREP. Summary of Product Characteristics. GlaxoSmithKline. 2025.
- NICE. ID6212. Available at https://www.nice.org.uk/guidance/indevelopment/gid-ta11203. Accessed September 2025.
▼This product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (available on the Apple App Store or Google Play Store). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.
September 2025 | PM-GB-BLM-WCNT-250013 (V1.0)
